Prevalent levels of RSV serum neutralizing antibodies in healthy adults outside the RSV-season

• Váldodahkkit: Johan L. Van Der Plas (Dahkki), Pauline Verdijk (Dahkki), Emilie M. J. Van Brummelen (Dahkki), Rienk E. Jeeninga (Dahkki), Meta Roestenberg (Dahkki), Jacobus Burggraaf (Dahkki), Ingrid M.C. Kamerling (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Taylor & Francis Group, 2020-06-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

One of the main challenges in early clinical research with respiratory syncytial virus (RSV) live-attenuated vaccines (LAVs) is to assess immunogenicity in healthy adults. Healthy adults will have preexisting levels of serum neutralizing antibodies that could prematurely neutralize the LAV and under...